Rain Oncology Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2023-10-12: Study NCT05932667; Company role Collaborator; Phase Phase 2; Status Terminated.
- 2023-05-19: Study NCT06090318; Company role Lead sponsor; Phase Phase 1, Phase 2; Status Withdrawn.
- 2023-04-17: Study NCT05758818; Company role Lead sponsor; Phase Phase 1; Status Terminated.
- 2022-03-07: Study NCT05313009; Company role Collaborator; Phase Phase 1, Phase 2; Status Terminated.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2023-10-12 | NCT05932667 Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer | Collaborator Lead: Institut Curie | Phase 2 | Terminated | Advanced or Metastatic Breast Cancer | 1 | 2023-11-30 |
| 2023-05-19 | NCT06090318 Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss | Lead sponsor | Phase 1, Phase 2 | Withdrawn | Advanced Solid Tumor; CDKN2A; NSCLC; Urothelial Carcinoma Bladder; Melanoma; Pancreas Adenocarcinoma; HNSCC; Renal Cell Carcinoma; Mesothelioma; Gastric Cancer | 0 | 2023-05-30 |
| 2023-04-17 | NCT05758818 A Study of Milademetan Administration on Cardiac Repolarization in Healthy Subjects | Lead sponsor | Phase 1 | Terminated | Cardiac Repolarization | 6 | 2023-06-08 |
| 2022-03-07 | NCT05313009 Tarlox and Sotorasib in Patients With KRAS G12C Mutations | Collaborator Lead: Medical University of South Carolina | Phase 1, Phase 2 | Terminated Results posted | Non-Small Cell Lung Cancer | 5 | 2023-12-31 |
| 2021-11-01 | NCT05012397 Milademetan in Advanced/Metastatic Solid Tumors | Lead sponsor | Phase 2 | Terminated Results posted | Solid Tumors; Head and Neck Carcinoma; Cholangiocarcinoma; Sarcoma; Lung Adenocarcinoma; Bladder Urothelial Carcinoma; Stomach Adenocarcinoma; Breast Cancer Invasive; Ovarian Carcinoma; Cervical Cancer; Non Small Cell Lung Cancer; Gastric Cancer; Biliary Tract Cancer; Melanoma; Pancreas Cancer; MDM2 Gene Amplification; Testicular Germ Cell Tumor; Adrenocortical Carcinoma | 40 | 2023-10-15 |
| 2021-07-14 | NCT04979442 Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma | Lead sponsor | Phase 3 | Terminated Results posted | Dedifferentiated Liposarcoma | 175 | 2023-10-01 |
| 2019-03-13 | NCT03805841 Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions | Lead sponsor | Phase 2 | Terminated Results posted | NSCLC, Stage IV; NSCLC Stage IIIB; NSCLC, Stage IIIC; NSCLC, Recurrent; EGFR Exon 20 Insertion Mutation; HER2-activating Mutation; ERBB Fusion; NRG1 Fusion | 41 | 2021-04-23 |
| 2015-08 | NCT02449681 Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin | Lead sponsor | Phase 2 | Terminated | Metastatic Head-and-neck Squamous-cell Carcinoma | 30 | 2017-01-31 |
| 2015-06 | NCT02454842 Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients | Lead sponsor | Phase 2 | Terminated | Non-small Cell Lung Cancer; NSCLC; Non-squamous NSCLC | 21 | 2017-01-31 |